NTLA

Intellia Therapeutics Inc

$17.40

0.48 (2.84%) Today

— up— down

Compare NTLA

Market Cap

$2.36B+76.3%

Revenue (TTM)

$77.94M+45.0%

Net Income (TTM)

$-493,728,564

EPS (TTM)

-3.53

Shares Out

139.72M

Open

$16.85

Previous Close

$16.92

Day Range

$16.72 – $17.83

52-Week Range

$7.95 – $28.25

Beta

1.78

Volume

1.93M

Avg Volume

5.76M

Analyst Rating

Buy

Exchange

NASDAQ NMS - GLOBAL MARKET

About NTLA

Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.